10. Outcomes of 3-Level Cervical Disc Arthroplasty Comparing with 3-Level Anterior Cervical Discectomy and Fusion
Hanzhi Yang,Jialun Chi,Zhiwen Xu,Yi Zhang,Rohan Boyapati,Thomas B Ramsey,Jesse Wang,Lawal Labaran,Xudong Joshua Li
DOI: https://doi.org/10.1016/j.spinee.2024.06.454
IF: 4.297
2024-01-01
The Spine Journal
Abstract:BACKGROUND CONTEXT Cervical disc arthroplasty (CDA) has emerged as a noninferior alternative to anterior cervical discectomy and fusion (ACDF). Few 3-level CDA clinical studies exist. Currently, CDAs above 2 levels have been used as off-labeled procedures across the United States and can be considered experimental by insurance companies. PURPOSE This study aims to study postoperative complications between 3-level CDA and 3-level ACDF. STUDY DESIGN/SETTING Retrospective cohort study. PATIENT SAMPLE In total, 2,901 3-level CDA patients and 14,378 3-level ACDF patients between 18–84 years old from 2010 to 2020 were identified. Patients with current or past etiologies of trauma, infection, or malignancy were excluded from the population. Both cohorts were then matched by age, gender, obesity, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, coronary artery disease, tobacco use, congestive heart failure, hyperlipidemia, peripheral vascular disease, hypertension, and depression. All patients had a minimum of 2 years of follow-up. OUTCOME MEASURES Ninety-day postoperative medical complications include intubation, dysphagia, pneumonia, pulmonary embolism, cerebrovascular accident, deep vein thrombosis, myocardial infarction, sepsis, acute kidney injury, and urinary tract infection. Ninety-day postoperative surgical complications include C5 palsy, recurrent laryngeal nerve palsy, wound complications, surgical site infection, and transfusion. Ninety-day emergency department (ED) visits and readmissions were documented. Two-year complications include instrumentation failure and revision. Four-year rate of revisions including anterior-only, posterior-only, and combined approaches were studied. Reoperations were included as any subsequent surgery, including fusion, decompression, and/or revision or removal of instrumentation. METHODS Demographics and preexisting comorbidities were assessed with the Pearson χ2 test. Multivariable logistic regression was used to determine the independent effects of CDA and ACDF on the postoperative outcomes after adjusting for demographic factors and pertinent comorbidities. PearlDiver Bellwether was used to conduct all statistical analyses via its research query interface. The common statistical metrics, including frequencies, mean values, and odds ratios (ORs), were collected by the Bellwether system using the R statistical package. Statistical significance was set at p < 0.05. RESULTS Three-level CDA had a lower rate of dysphagia to ACDF (2.4% vs 3.7%; OR 0.64, 95% CI 0.49-0.82; p < 0.001) and pneumonia at 90-day (0.5% vs 0.9%; OR 0.52, 95% CI 0.28-0.87; p = 0.022). CDA patients also had decreased rates of wound complications at 90 days (0.7% vs 1.3%; OR 0.53, 95% CI 0.32-0.82; p = 0.007) and surgical site infections (0.4% vs 0.8%; OR 0.52, 95% CI 0.27-0.90; p = 0.033). CDA patients had a reduced rate of ED visits within 90 days (7.1% vs 9.3%; OR 0.72, 95% CI 0.62-0.84; p < 0.001) and lower rates of readmission at 90 days (1.7% vs 2.8%; OR 0.58, 95% CI 0.42-0.78; p < 0.001). At 4 years, 786 CDA patients and 3,890 ACDF patients were left. At the 2-year follow-up, CDA patients experienced a lower rate of instrumentation failure (1.5% vs 3.0%; OR 0.49, 95% CI 0.25-0.87; p = 0.023). At 4 years, the CDA group had a lower posterior revision rate (2.0% vs 3.4%; OR 0.57, 95% CI 0.32-0.95; p = 0.042), and less overall revision rate (5.0% vs 7.4%; OR 0.64, 95% CI 0.45-0.90; p = 0.014). CONCLUSIONS This study represents the largest comparative study examining clinical outcomes following 3-level CDA. 3-level CDA projected itself as a safe and noninferior procedure to ACDF in this study. Further long-term studies are warranted. FDA Device/Drug Status This abstract does not discuss or include any applicable devices or drugs.